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Abstract: Brain neurons form synapses throughout the life span. This process is initiated 
by neuronal depolarization, however the numbers of synapses thus formed depend on brain 
levels of three key nutrients—uridine, the omega-3 fatty acid DHA, and choline. Given 
together, these nutrients accelerate formation of synaptic membrane, the major component 
of synapses. In infants, when synaptogenesis is maximal, relatively large amounts of all 
three nutrients are provided in bioavailable forms (e.g., uridine in the UMP of mothers’ 
milk and infant formulas). However, in adults the uridine in foods, mostly present at RNA, 
is not bioavailable, and no food has ever been compelling demonstrated to elevate plasma 
uridine levels. Moreover, the quantities of DHA and choline in regular foods can be 
insufficient for raising their blood levels enough to promote optimal synaptogenesis.  
In Alzheimer’s disease (AD) the need for extra quantities of the three nutrients is 
enhanced, both because their basal plasma levels may be subnormal (reflecting impaired 
hepatic synthesis), and because especially high brain levels are needed for correcting the  
disease-related deficiencies in synaptic membrane and synapses. 
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1. Introduction 
The recognition that nutrient intake can affect the rate at which the brain makes new synapses  
arose largely from basic-science studies performed in MIT’s Department of Brain and Cognitive 
Sciences between 1999 and 2012 [1–4]. As described below, these studies showed that when  
three nutrients—uridine (as its monophosphate, UMP); the omega-3 fatty acid DHA (or EPA, which is 
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equally effective [4]); and choline—are consumed together, brain cells produce more of the specialized 
membranes [1] used for forming dendritic spines [2,3], the immediate anatomic precursor of synapses. 
The nutrients also improve cognitive test scores in both impaired and normal experimental animals [2,4]. 
Based on these findings, and on the consensus that a deficiency in synapses underlies the memory 
disorder seen in early Alzheimer’s disease [5], a mixture containing the three nutrients plus others  
that enhance their efficacy, SOUVENAID® was formulated and tested, and found to improve  
memory scores [6] and the connectivities between brain regions [7] among patients with early 
Alzheimer’s Disease. 
The ability of the brain to make more phosphatidylcholine (PC), and related membrane constituents 
when presented with additional uridine, DHA, and choline, requires that the enzymes which catalyze 
the steps in PC synthesis have a special biochemical property: Each enzyme must exhibit unusually 
poor affinity for its substrate, so that, at the uridine, DHA, and choline concentrations normally present 
in brain cells, many enzyme molecules will not be attached to their substrate and, thus, will not be able 
to act on it. However, when additional substrate is provided—by administering the nutrients to raise 
their blood levels—more enzyme molecules become engaged, and more of their product is formed [2].  
We had first observed a similar “precursor-dependence” many years earlier involving the conversion 
of a different nutrient, the amino acid tryptophan, to serotonin, a neurotransmitter [8]: Giving animals 
tryptophan rapidly increased the formation and release of brain serotonin. Similar precursor-dependence 
was subsequently shown to characterize numerous other neurotransmitters [9]. 
The concentrations of uridine, DHA, and choline required for engaging just half of the molecules of 
each enzyme needed for converting choline to PC (i.e., each enzyme’s Michaelis-Menten constant [Km]) 
were found to be very high in relation to their actual brain concentrations. Hence, administering each 
of the nutrients does in fact increase the production, and, ultimately, the levels of brain PC [1]. 
Moreover, the effect of giving uridine, DHA, and choline together is additive or greater. An additional 
biochemical mechanism activated by the uridine in SOUVENAID® enables the brain also to increase 
production of the special proteins found in synaptic membranes. It involves the activation of P2Y 
receptors, a particular family of brain receptors that can affect neuronal differentiation and synaptic 
protein synthesis [10]. P2Y receptor activation is also involved in the processes that shape the  
newly-formed membrane into neurites, dendritic spines, and synapse [10]. 
2. Control of Synaptogenesis 
Most of the communications that take place between a brain neuron that transmits a signal and  
one that receives that signal occur at synapses. These are highly specialized structures, which include a 
presynaptic terminal budding from the transmitting neuron’s axon; the postsynaptic membrane, usually 
on one of the receiving neuron’s dendrites; and the space between the neurons—the synaptic cleft. 
Presynaptic terminals make and store the neuron’s neurotransmitter, and release some of it into the 
synaptic cleft when the neuron is depolarized. The postsynaptic membranes contain receptors to which 
the neurotransmitter can then attach, as well as other protein molecules which mediate the functional 
consequences of receptor activation. Pre- and post-synaptic membranes are composed principally of 
phosphatides like PC; other phospholipids and cholesterol; and particular proteins, many of which are 
confined to synaptic structures. 
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The postsynaptic membranes on which glutamate, the most widely-used excitatory brain 
neurotransmitter, acts contain large numbers of dendritic spines, as well as postsynaptic densities 
(PSD) which house various proteins that mediate most of the functional consequences of receptor 
activation. For example, some of these proteins open or close “pores” in the membranes, thereby 
allowing specific ions which affect the cell’s voltage to pass in or out; others activate enzymes that 
synthesize second-messenger compounds (like cyclic-AMP or diacylglycerol), which affect gene 
expression and the overall metabolism of the post-synaptic neuron. 
The formation of a new synapse (by, for example, hippocampal neurons that use glutamate as their 
neurotransmitter) can be initiated by the coming together of what will become a presynaptic terminal 
and a dendritic spine. Thus the availability of dendritic spines is an important factor controlling the 
rate of synaptogenesis. This number can be increased by various treatments (e.g., by giving the 
hormone ghrelin—which also enhances memory performance and long-term potentiation, a form of 
learning), or decreased by Alzheimer’s and other dementia-producing diseases. The sparsity of 
dendritic spines in AD brain [11] probably causes a decrease in the formation of new synapses. This 
may partially explain the decreased number of cortical synapses and the consequent memory 
impairment observed early in the course of the disease. 
Although most brain synapses are formed prenatally or during early postnatal development, each 
survives for only days to months, and must be renewed periodically throughout the individual’s life 
span. This continuing necessity is probably a major factor underlying the brain’s plasticity and the 
individual’s ability to learn, since it allows specific, newly-formed synapses to be associated with 
newly-learned material. Early in development, most synaptogenesis occurs in the absence of neuronal 
depolarization and neurotransmitter release. In adulthood, however, the rate at which new synapses 
form, and the ways their connections become configured, are largely governed by neuronal activity. 
This allows very active synapses to facilitate the formation of additional functionally-related synapses. 
However, the magnitude of the increase in synaptogenesis among active neurons is apparently 
modulated by nutrient availability, specifically of uridine, DHA, and choline [1]. 
3. Biosynthesis of Membrane Phosphatides, Synaptic Proteins, Neurites, and Dendritic Spines: 
Effects of Uridine, Dha, and Choline 
3.1. Membrane Phosphatides 
All cells utilize DHA and other fatty acids (e.g., EPA); uridine; and choline to form the phosphatide 
compounds that constitute the major components of their membranes. PC, the most abundant 
phosphatide in brain, is synthesized from these precursor-nutrients by a set of enzymes that comprise 
the CDP-choline cycle (or “Kennedy Cycle”). This biochemical pathway also generates a related 
membrane constituent, the phosphatide phosphatidylethanolamine (PE). Phosphatidylserine (PS),  
the third major membrane phosphatide, is produced by exchanging a serine molecule for the choline in 
PC or the ethanolamine in PE. Sphingomyelin, the other major choline-containing brain constituent,  
is formed from PC. Thus, all of the principal lipid components of synaptic membranes are affected by 
the rate at which PC is being formed. In addition, since each of the reactions needed to convert 
choline, uridine, and DHA to PC is catalyzed by a low-affinity enzyme, blood levels of the three 
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nutrient-precursors can determine not only PC’s rate of synthesis but also the rates at which almost all of 
the brain’s membrane lipids are produced. When all three of the nutrients are provided concurrently the 
resulting increase in PC production is greater than the sum of the increases produced by giving each 
separately [1,2]. This probably occurs because if just one of the nutrient-precursors were to be 
provided, the concentrations of the other two would continue to be limiting. 
The CDP-choline cycle involves three sequential enzymatic reactions [2]: In the first, catalyzed by 
choline kinase (CK), a phosphate group is transferred from ATP to the hydroxyl oxygen of choline, 
yielding phosphocholine. The second reaction, catalyzed by CTP:phosphocholine cytidylyltransferase 
(CT), transfers cytidine-5′-monophosphate (CMP), a portion of the high-energy CTP molecule, to the 
phosphocholine, yielding cytidine-5′-diphosphocholine (also known as CDP-choline, or as citicoline). 
(As discussed below, most of the CTP that the human brain uses for PC synthesis comes from 
circulating uridine, there being little or no free cytidine in human blood) [12]. The third and last 
reaction, catalyzed by the enzyme CDP-choline:1,2,diarylglycerol cholinephosphotransferase (CPT), 
transfers the choline moiety from CDP-choline to the free hydroxyl group of diacylglycerol (DAG), 
yielding the PC. As described below, the brain obtains all three of these PC precursors mostly or 
entirely from the blood stream. 
Thus, administering choline increases brain phosphocholine levels in rats and humans because CK’s 
Km for choline (2.6 mM) is much higher than usual brain choline levels (30–60 µM) [2]. Similarly, 
administering uridine increases brain levels of UTP and then CTP [2], and giving DHA increases the 
concentration of DAG molecules likely to be used for production of PC (because one of their two fatty 
acids happens to be DHA, an omega-3 compound). 
3.2. Proteins Localized in Pre- and Post-Synaptic Membranes 
Administration together of DHA, uridine (as UMP) and choline also increases the levels of proteins 
that are localized within presynaptic and postsynaptic membranes (for example, synapsin-1P; syntaxin-3; 
PSD-95), but not of other proteins, like beta-tubulin, which are found all over the brain [1–3]. The 
increase in synaptic proteins probably results from the additional action of uridine described above, 
i.e., its ability (shared with uridine-containing nucleotides like UTP) to activate P2Y receptors in the 
brain [10]. Nucleotides like UTP activate a variety of receptor subtypes that stimulate either ion fluxes 
(P2X) or intracellular metabolic processes (P2Y). The P2Y receptors in brain (P2Y2; P2Y4; P2Y6) 
tend to be specific for uridine-containing compounds. Their activation increases intracellular concentrations 
of the second-messengers DAG, inositol triphosphate, and calcium. 
3.3. Neurite Outgrowth 
Activation of P2Y receptors by uridine or UTP also affects the outgrowth, from neuron-derived 
cells, of neurites [10] (which, like dendritic spines, can be precursors for synapses, and are principally 
composed of membranes). P2Y activation can also stimulate neuronal differentiation; the branching of 
the neurites; protein synthesis; expression of neurofilament proteins present in neurites; neurotransmitter 
release; and the enhancement of long-term potentiation. All of these effects can be blocked by drugs 
that antagonize P2Y receptors. The increase in neurites among cells exposed to uridine or UTP [10] 
Nutrients 2014, 6 1705 
 
 
provided the first demonstration that phosphatide precursors could alter cellular anatomy, as well as 
biochemical indices. 
P2Y2 receptors in patients with AD apparently are deficient in the parietal cortex [13]—a brain 
region important for memory. This suggests that increasing brain levels of the receptor ligand UTP—by 
administering the UMP in SOUVENAID®—may partially compensate for the P2Y receptor deficiency. 
Interestingly, uridine is not unique in being able to regulate cell differentiation and metabolism by 
two distinct mechanisms, acting both as a receptor agonist and as a bulk precursor of the CTP needed 
for phosphatide synthesis. Diacylglycerol also acts in two ways, both as a potent “second messenger” 
that activates a number of enzymes and other proteins, and also, like uridine, as a bulk precursor in 
phosphatide synthesis. 
3.4. Incorporation of Synaptic Membrane into Dendritic Spines 
The numbers of dendritic spines in particular brain regions are highly correlated with the numbers 
of synapses [3], and it has been proposed that “more than 90% of excitatory synapses occur on 
dendritic spines” [2]. This suggests that processes that damage the spines or, conversely, that increase 
spine number will cause parallel changes in synapse number. The formation of new dendritic spines in 
the hippocampus can be initiated by synaptic inputs that depolarize CA1 pyramidal neurons and  
cause long-term potentiation. This effect is probably mediated by enhanced calcium influx into the 
CA1 neurons. 
The effects on hippocampal dendritic spine number of administering the omega-3 fatty acid DHA, 
alone or with UMP, were compared after one to four weeks of daily treatment [3]. DHA alone caused  
dose-related increases in spine number, as well as in membrane phosphatides and synaptic proteins;  
its effects were doubled if animals also received UMP. Treated animals also exhibited improvements 
in cognitive performance as assessed using the Morris water maze test and various other tests based on 
traversing mazes [4]. In contrast, administration of the omega-6 fatty acid arachidonic acid affected 
neither spine density nor membrane composition. Similar positive effects of giving DHA plus UMP 
were observed in weanlings whose mothers consumed the nutrients for 10 days prior to parturition, and 
for 21 days while nursing. 
In summary, the simultaneous provision of DHA, uridine (as UMP) and choline increases brain 
phosphatides and synaptic proteins, the main constituents of synaptic membranes, as well as dendritic 
spines, the immediate anatomic precursor for new synapses. 
4. Sources of Brain and Blood Uridine, Dha, and Choline 
4.1. Blood-Brain Transport 
4.1.1. Uridine 
Circulating uridine is carried across cellular membranes in all tissues, including the brain, by two 
families of transport proteins: a low-affinity, facilitated-diffusion system—which probably operates 
only when plasma uridine levels have been increased substantially, (e.g., after administration of a 
UMP source, like mothers’ milk) and a high-affinity system, which operates under physiological 
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conditions [2], and which can maintain a concentration gradient between brain and blood. On entering 
brain cells uridine is phosphorylated, initially to UMP, and subsequently retained. 
4.1.2. DHA 
DHA enters the brain, and then brain cells, both by a simple diffusion mechanism and through the 
action of one or more transport proteins [2]. Once inside cells it is activated by combining with -CoA, 
and the DHA-CoA is used for DAG. The enzyme that catalyzes DHA’s acylation has a low affinity 
relative to usual brain levels, so that raising blood DHA levels rapidly increases DHA’s uptake into 
and retention by brain cells. 
4.1.3. Choline 
Choline molecules (but not PC nor its metabolite lyso-PC) enter the brain principally by facilitated 
bidirectional diffusion, mediated by a transport protein in the endothelial cells lining the brain’s 
capillaries [2]. The rate of choline’s entry depends on the gradient between its concentrations in the 
brain’s extracellular fluid (ecf) and in the blood. Once in the ecf, choline can enter cells by a 
ubiquitous, low-affinity transport system or, in the terminals of acetylcholine-producing neurons, by a 
high-affinity system. 
4.2. Sources of Blood Uridine, DHA, and Choline 
4.2.1. Blood Uridine 
The sources of uridine in human blood depend largely on the age of the human: In infancy, as 
described below, mother’s milk or infant formulas can provide substantial uridine in the form of UMP. 
In adulthood however, almost all of the uridine in the blood has been synthesized by the liver—unless 
one consumes a UMP-fortified mixture, like SOUVENAID®. 
In humans, uridine is apparently the only pyrimidine nucleoside in the circulation [12]: plasma 
cytidine levels—which are high in, for example, rodents—are very low, even after administration of a 
cytidine source, because the cytidine is rapidly converted to uridine in the human liver. Hence, plasma 
uridine is the sole circulating precursor for CTP and other cytidine-containing compounds in human 
brain. The uridine in blood of adult humans is synthesized in the liver as UMP, and secreted as such 
into the circulation. In contrast, the uridine in the blood of infants can derive from the UMP in mothers’ 
milk or, since the 1990s, from the UMP added to infant formulas [14,15] as a “conditionally-essential 
nutrient” [14–16] thought to promote the growth of rapidly-dividing gastrointestinal and immune cells [16]. 
Uridine is also present in most foods consumed after infancy principally in the form of RNA. But 
unlike free uridine or the uridine in UMP, the uridine in RNA is not generally bioavailable [17], and no 
uridine-containing adult food has ever been compellingly demonstrated to raise plasma uridine levels 
in humans. As Gasser, et al. wrote in 1981 [17]: “The liver appears to degrade essentially all incoming 
uridine contained in the portal drainage derived from intestinal absorption and peritoneal organs. 
Hepatic pools of acid-soluble nucleosides [e.g., UMP] formed almost completely by de novo synthesis, 
are responsible for the uridine compounds in plasma leaving the liver through the hepatic vein.” It can 
be conjectured that one special advantage that accrues to infants by consuming mother’s milk, a source 
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of bioavailable uridine, relates to their need for large amounts of uridine to produce sufficient synaptic 
membrane for the rapidly-growing brain. In addition, if AD patients with depleted cortical synapses 
also need to accelerate synaptic membrane synthesis, then uridine, as such or in its most bioavailable 
form, UMP; also becomes for them a “conditionally essential nutrient”. 
Plasma uridine levels are apparently subnormal in patients with very mild AD [18,19]. The rates at 
which livers of AD patients synthesize and secrete uridine or UMP apparently have not yet been examined. 
4.2.2. Sources of Blood DHA 
Circulating DHA also can derive both from endogenous synthesis (from alpha-linolenic acid [ALA], 
in the liver) and from consumption of DHA-rich foods (e.g., fatty fish). The enzymatic conversion of 
ALA to DHA is reportedly impaired in some patients with AD [20] because of a genetic lesion that 
lowers the activity of perioxisomal D-bifunctional protein, the enzyme that catalyzes the last step in 
this conversion. Hence DHA levels in the plasma [21], liver, and various brain regions of AD patients 
are reduced. Moreover the ratio in liver of the enzyme’s product—DHA—to its substrate—linolenic 
acid—is subnormal, and correlates with AD patients’ abnormally low scores [20] in a standard test of 
cognition (MMSE). 
The existence of this genetic lesion, which may constitute a risk factor for AD, suggests that AD 
may involve more than just the brain. It also indicates that AD patients need a supplemental source of 
DHA both to obtain normal blood and tissue DHA levels and to promote synaptogenesis. Another 
metabolic factor that might affect plasma DHA levels in AD patients is the concurrent reduction in 
plasma levels of three vitamins [22]—B12, folate, and B6—needed for regenerating the methyl groups 
in methionine. This reduction impairs hepatic choline synthesis, as discussed below, and may in itself 
affect plasma DHA levels. 
4.2.3. Sources of Blood Choline 
Like uridine and DHA, plasma choline can derive both from its hepatic synthesis—as PC, formed 
from the B-vitamin-dependent sequential methylation of PE, which can then be hydrolyzed to free 
choline—and from dietary sources (e.g., egg yolks, principally in the form of PC). A recommended 
dietary intake of choline by normal adults has been proposed as being about half a gram per day, 
however, many people—particularly the aged, and women in general including pregnant women—often 
fail to attain this level [23,24]. Moreover, basal dietary choline requirements may be significantly 
greater among the many individuals who have common variations in certain gene alleles for hepatic 
enzymes, i.e., PEMT, which converts PE to PC, or for 5,10-methylenetetrahydrofolate dehydrogenase 
[MTHFR]) [23,24]: Premenopausal women with the allele for the less active MTHFR were found to be 
15 times more susceptible than control subjects to developing organ dysfunction when placed on a 
low-choline diet [24]. 
To some extent an increased need for dietary choline—as occurs in people who, usually-unknowingly, 
carry such alleles, or in AD patients who require additional choline to enhance synaptic membrane 
synthesis—can be satisfied by providing oral choline. However when doses in excess of 500 mg are 
consumed many subjects develop an unacceptable “fishy” body odor, caused by choline’s degradation 
to trimethylamine by bacteria in the large intestine. Hence SOUVENAID® also contains, besides 
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choline, three vitamins—B12, folate, and B6—which promote endogenous choline synthesis in the 
liver [22]. 
5. Conclusions 
Although the formation of new synapses is triggered by neuronal firing, the number of synapses that 
form can be modulated when three circulating nutrients, uridine, DHA, and choline are administered 
together. This is because cellular levels of the nutrients control the saturation of key enzymes in the 
synthesis of the phosphatides in synaptic membranes. One of the nutrients, uridine, also affects 
synaptogenesis by activating P2Y receptors in the brain. 
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